Sajja Venkatesh on the Results of CREST-2 Trial
Sajja Venkatesh, Interventional Neurologist, FNB-NeuroVascular Intervention at Apollo Hospitals, shared on LinkedIn:
”CREST-2 Trial: Carotid artery stenting (CAS) vs Carotid Endarterectomy (CEA) for asymptomatic high-grade carotid stenosis (≥70%) who have not had recent stroke symptoms,
- Addition of CAS resulted in a reduced risk of a composite of perioperative stroke, death, or ipsilateral stroke within a 4 year timeframe, surpassing the outcomes achieved through intensive medical management alone.
- Conversely, CEA did not demonstrate a statistically significant advantage.
Primary Outcome:
– Stenting Trial: The 4-year incidence of stroke or death was significantly lower in the stenting group (2.8%) compared to the medical-therapy group (6.0%), with an absolute risk reduction of 3.2 percentage points (P=0.02).
– Endarterectomy Trial: No significant difference was observed between the endarterectomy group (3.7%) and the medical-therapy group (5.3%) (P=0.24).”
Read the full article here.
Article: Medical Management and Revascularization for Asymptomatic Carotid Stenosis
Authors: CREST-2 Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 17, 2026, 18:11Ossama Mansour: Landmark MENA Guidelines for Acute Ischemic Stroke Management
-
Mar 17, 2026, 17:48Andrea Van Beek: Improving DOAC Adherence Saves Lives
-
Mar 17, 2026, 17:43Soumen Bhattacharyya: Microangiopathic Hemolytic Anemia Is Often a Hematologic Clue to Underlying Malignancy
-
Mar 17, 2026, 17:37Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
-
Mar 17, 2026, 17:31Armghan Ans: The 2026 Stroke Guidelines Are Excellent, Now the Hard Part
-
Mar 17, 2026, 17:26Danny Hsu: Navigating a Rebalanced Hemostatic State in Decompensated Cirrhosis
-
Mar 17, 2026, 17:21Matías J Alet on Acute Ischemic Stroke With Low NIHSS at NeuroQuality
-
Mar 17, 2026, 17:16S1PR4 Controls Platelet Fibrinogen Binding and Thrombus Formation – JTH
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs